First-trimester markers of aneuploidy in women positive for HIV

M. D. Savvidou; I. Samuel; A. Syngelaki; M. Poulton; K. H. Nicolaides

doi:10.1111/j.1471-0528.2010.02767.x

First-trimester markers of aneuploidy in women positive for HIV

M. D. Savvidou^*, I. Samuel, A. Syngelaki, M. Poulton, K. H. Nicolaides

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Objective

To investigate whether the sonographic and maternal serum biochemical markers used in first-trimester screening for chromosomal abnormalities are altered in pregnancies affected by maternal HIV infection.

Design

Nested case-control study.

Setting

Routine antenatal visit in a teaching hospital.

Population

Ninety HIV-positive and 450 HIV-negative pregnant women.

Methods

Findings from first-trimester antenatal visit for calculation of the risk for chromosomal abnormalities were compared between HIV-positive (treated and untreated) and HIV-negative women.

Main outcome measures

First-trimester maternal serum free beta human chorionic gonadotrophin (free beta-hCG) pregnancy-associated plasma protein-A (PAPP-A) and fetal nuchal translucency thickness (NT), were compared.

Results

There were no statistically significant differences between the HIV-positive and HIV-negative women in the median maternal levels of free beta-hCG, PAPP-A and fetal NT. However, within the HIV-positive group those receiving antiretroviral treatment (n = 41) had a significantly lower median multiple of the median (MoM) for free beta-hCG (0.74, interquartile range [IQR] 0.45-1.32 MoM) than HIV-positive women on no treatment (1.03, IQR 0.76-1.85 MoM; P = 0.006) and HIV-negative women (1.0, IQR 0.68-1.47 MoM; P = 0.003). There was no correlation between the level of free beta-hCG or PAPP-A and maternal viral load or CD4+ count.

Conclusions

Maternal levels of free beta-hCG in treated HIV-positive pregnant women were lower compared with those in non-treated HIV-positive and HIV-negative women, whereas the PAPP-A levels and fetal NT remained unaltered.

Original language	English
Pages (from-to)	844-848
Number of pages	5
Journal	Bjog-An international journal of obstetrics and gynaecology
Volume	118
Issue number	7
DOIs	https://doi.org/10.1111/j.1471-0528.2010.02767.x
Publication status	Published - Jun 2011

Keywords

Chromosomal abnormalities
first trimester
free beta-human chorionic gonadotrophin
HIV
pregnancy
pregnancy-associated plasma protein-A
HUMAN CHORIONIC-GONADOTROPIN
HUMAN-IMMUNODEFICIENCY-VIRUS
PLASMA PROTEIN-A
FREE BETA-HCG
PREGNANT-WOMEN
NUCHAL TRANSLUCENCY
TRISOMY-21
MULTICENTER
IMPACT
INFECTION

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1471-0528.2010.02767.x

Cite this

@article{9d5310fc3a9b464eacf9c2aa3ea552e2,

title = "First-trimester markers of aneuploidy in women positive for HIV",

abstract = "ObjectiveTo investigate whether the sonographic and maternal serum biochemical markers used in first-trimester screening for chromosomal abnormalities are altered in pregnancies affected by maternal HIV infection.DesignNested case-control study.SettingRoutine antenatal visit in a teaching hospital.PopulationNinety HIV-positive and 450 HIV-negative pregnant women.MethodsFindings from first-trimester antenatal visit for calculation of the risk for chromosomal abnormalities were compared between HIV-positive (treated and untreated) and HIV-negative women.Main outcome measuresFirst-trimester maternal serum free beta human chorionic gonadotrophin (free beta-hCG) pregnancy-associated plasma protein-A (PAPP-A) and fetal nuchal translucency thickness (NT), were compared.ResultsThere were no statistically significant differences between the HIV-positive and HIV-negative women in the median maternal levels of free beta-hCG, PAPP-A and fetal NT. However, within the HIV-positive group those receiving antiretroviral treatment (n = 41) had a significantly lower median multiple of the median (MoM) for free beta-hCG (0.74, interquartile range [IQR] 0.45-1.32 MoM) than HIV-positive women on no treatment (1.03, IQR 0.76-1.85 MoM; P = 0.006) and HIV-negative women (1.0, IQR 0.68-1.47 MoM; P = 0.003). There was no correlation between the level of free beta-hCG or PAPP-A and maternal viral load or CD4+ count.ConclusionsMaternal levels of free beta-hCG in treated HIV-positive pregnant women were lower compared with those in non-treated HIV-positive and HIV-negative women, whereas the PAPP-A levels and fetal NT remained unaltered.",

keywords = "Chromosomal abnormalities, first trimester, free beta-human chorionic gonadotrophin, HIV, pregnancy, pregnancy-associated plasma protein-A, HUMAN CHORIONIC-GONADOTROPIN, HUMAN-IMMUNODEFICIENCY-VIRUS, PLASMA PROTEIN-A, FREE BETA-HCG, PREGNANT-WOMEN, NUCHAL TRANSLUCENCY, TRISOMY-21, MULTICENTER, IMPACT, INFECTION",

author = "Savvidou, {M. D.} and I. Samuel and A. Syngelaki and M. Poulton and Nicolaides, {K. H.}",

year = "2011",

month = jun,

doi = "10.1111/j.1471-0528.2010.02767.x",

language = "English",

volume = "118",

pages = "844--848",

journal = "Bjog-An international journal of obstetrics and gynaecology",

issn = "1470-0328",

publisher = "Blackwell Publishing Ltd",

number = "7",

}

TY - JOUR

T1 - First-trimester markers of aneuploidy in women positive for HIV

AU - Savvidou, M. D.

AU - Samuel, I.

AU - Syngelaki, A.

AU - Poulton, M.

AU - Nicolaides, K. H.

PY - 2011/6

Y1 - 2011/6

N2 - ObjectiveTo investigate whether the sonographic and maternal serum biochemical markers used in first-trimester screening for chromosomal abnormalities are altered in pregnancies affected by maternal HIV infection.DesignNested case-control study.SettingRoutine antenatal visit in a teaching hospital.PopulationNinety HIV-positive and 450 HIV-negative pregnant women.MethodsFindings from first-trimester antenatal visit for calculation of the risk for chromosomal abnormalities were compared between HIV-positive (treated and untreated) and HIV-negative women.Main outcome measuresFirst-trimester maternal serum free beta human chorionic gonadotrophin (free beta-hCG) pregnancy-associated plasma protein-A (PAPP-A) and fetal nuchal translucency thickness (NT), were compared.ResultsThere were no statistically significant differences between the HIV-positive and HIV-negative women in the median maternal levels of free beta-hCG, PAPP-A and fetal NT. However, within the HIV-positive group those receiving antiretroviral treatment (n = 41) had a significantly lower median multiple of the median (MoM) for free beta-hCG (0.74, interquartile range [IQR] 0.45-1.32 MoM) than HIV-positive women on no treatment (1.03, IQR 0.76-1.85 MoM; P = 0.006) and HIV-negative women (1.0, IQR 0.68-1.47 MoM; P = 0.003). There was no correlation between the level of free beta-hCG or PAPP-A and maternal viral load or CD4+ count.ConclusionsMaternal levels of free beta-hCG in treated HIV-positive pregnant women were lower compared with those in non-treated HIV-positive and HIV-negative women, whereas the PAPP-A levels and fetal NT remained unaltered.

AB - ObjectiveTo investigate whether the sonographic and maternal serum biochemical markers used in first-trimester screening for chromosomal abnormalities are altered in pregnancies affected by maternal HIV infection.DesignNested case-control study.SettingRoutine antenatal visit in a teaching hospital.PopulationNinety HIV-positive and 450 HIV-negative pregnant women.MethodsFindings from first-trimester antenatal visit for calculation of the risk for chromosomal abnormalities were compared between HIV-positive (treated and untreated) and HIV-negative women.Main outcome measuresFirst-trimester maternal serum free beta human chorionic gonadotrophin (free beta-hCG) pregnancy-associated plasma protein-A (PAPP-A) and fetal nuchal translucency thickness (NT), were compared.ResultsThere were no statistically significant differences between the HIV-positive and HIV-negative women in the median maternal levels of free beta-hCG, PAPP-A and fetal NT. However, within the HIV-positive group those receiving antiretroviral treatment (n = 41) had a significantly lower median multiple of the median (MoM) for free beta-hCG (0.74, interquartile range [IQR] 0.45-1.32 MoM) than HIV-positive women on no treatment (1.03, IQR 0.76-1.85 MoM; P = 0.006) and HIV-negative women (1.0, IQR 0.68-1.47 MoM; P = 0.003). There was no correlation between the level of free beta-hCG or PAPP-A and maternal viral load or CD4+ count.ConclusionsMaternal levels of free beta-hCG in treated HIV-positive pregnant women were lower compared with those in non-treated HIV-positive and HIV-negative women, whereas the PAPP-A levels and fetal NT remained unaltered.

KW - Chromosomal abnormalities

KW - first trimester

KW - free beta-human chorionic gonadotrophin

KW - HIV

KW - pregnancy

KW - pregnancy-associated plasma protein-A

KW - HUMAN CHORIONIC-GONADOTROPIN

KW - HUMAN-IMMUNODEFICIENCY-VIRUS

KW - PLASMA PROTEIN-A

KW - FREE BETA-HCG

KW - PREGNANT-WOMEN

KW - NUCHAL TRANSLUCENCY

KW - TRISOMY-21

KW - MULTICENTER

KW - IMPACT

KW - INFECTION

U2 - 10.1111/j.1471-0528.2010.02767.x

DO - 10.1111/j.1471-0528.2010.02767.x

M3 - Article

SN - 1470-0328

VL - 118

SP - 844

EP - 848

JO - Bjog-An international journal of obstetrics and gynaecology

JF - Bjog-An international journal of obstetrics and gynaecology

IS - 7

ER -

First-trimester markers of aneuploidy in women positive for HIV

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this